FIND A GREATER
Through a patented and proprietary process , APIC A2M is isolated and concentrated from your blood to biologically clean out your joint or disc space and provide a healthy enviroment for repair.
How APIC A2M WORKS
For the majority of patients with pain, their arthritic joint or disc space houses more destructive enzymes than the body can handle. While the APIC A2M Molecule is our body’s own defense mechanism, it is unable to enter the joint or disc space in large enough quantities due to its large size and complex structure. As a result, it is necessary to inject additional isolated concentrated APIC A2M into the affected area to restore balance and pain relief.
An injection of isolated concentrated APIC A2M, derived from your own blood and placed directly into your joint or disc space, can provide the necessary amount of APIC A2M to bind and remove these destructive proteases.
What does APIC A2M have to do with solving my joint or back pain?
APIC Alpha-2-Macroglobulin (A2M) therapy is different from other treatments. APIC A2M is a naturally occurring molecule found in your blood, which when administered in highly concentrated doses, acts as a powerful protector against cartilage breakdown. APIC A2M eliminates inflammation, attaches to, and removes the destructive enzymes and proteases, which damage cartilage cells and tissues within the joint or disc space.
Early Treatment Equals Better Recovery
For patients suffering from joint or back pain, APIC A2M therapy is an exciting advancement in orthopedic science resulting from years of research. Early treatments of this miracle molecule delay the need for more aggressive and costly procedures, including surgery. Your current treatment may only be managing the symptoms of your joint or back pain — not addressing the root cause. Though most patients find these types of treatments offer temporary relief they are not focusing on the underlying source of arthritic joint and back pain.
Breakthrough therapy indicator
Research has identified the “pain protein” Fibronectin-Aggrecan Complex (FAC) as a link with painful inflammation and cartilage breakdown. Your doctor can test your synovial fluid for the presence of FAC and determine if you are an appropriate candidate for APIC A2M Therapy.
To learn more, read these articles about APIC A2M
Cytokine evaluation in individuals
The pathophysiology underlying degenerative disc disease and its implication in painful syndromes remain unclear. However, spine magnetic resonance imaging (MRI)
Does the presence of the fibronectin-aggrecan
Protein biomarkers associated with lumbar disc disease have been studied as diagnostic indicators and therapeutic targets. Recently, a cartilage degradation product,
Outcome of Lumbar Epidural Steroid Injection
A single-center, prospective, consecutive case series of patients undergoing epidural lavage before the treatment of radiculopathy due to lumbar disc herniation.
Are Persistently Symptomatic Vertebral Compression
A case-control study with prospectively collected samples for laboratory analysis in a series of patients with spinal fragility fractures and a series of patients without fracture
Is the Fibronectin-Aggrecan Complex
To investigate the presence of inflammatory cytokines and the fibronectinaggrecan complex (FAC) in persons undergoing surgical treatment for cervical radiculopathy
Does a Fibronectin and Aggrecan Complex
To determine the presence of a fibronectin-aggrecan complex (FAC) in the disk space of persons with chronic low back pain as relates to provocative diskography.
A critical evaluation of discography
The study is a prospective observational study of 48 continuous patients with symptomatic lumbar degenerative disk disease. Each patient underwent discography, MRI,
Biologic Augmentation of Rotator
Clinical studies have demonstrated a high rate of incomplete healing of rotator cuff tendon repair. Since healing of such a repair is dependent on bone ingrowth into the repaired tendon
PROPERTIES OF THE AMNIOTIC MEMBRANE
An important component of tissue engineering (TE) is the supporting matrix upon which cells and tissues grow, also known as the scaffold. Scaffolds must easily integrate with host tissue
Sutureless Fixation of Amniotic Membrane
1 Department of Ophthalmology, Klinikum Chemnitz gGmbH, Chemnitz, Germany, 2 Institute of Anatomy, Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany,
Adipose stem cells for intervertebral disc regeneration
New regenerative treatment strategies are being developed for intervertebral disc degeneration of which the implantation of various cell types is promising.
Applications of Amniotic Membrane
The amniotic membrane (AM) and amniotic fluid (AF) have a long history of use in surgical and prenatal diagnostic applications, respectively. In addition
Amniotic membrane used to repair human articular cartilage
The authors cultivated the chondrocytes (cells that form part of the cartilaginous tissue), isolated from human articular cartilage, on the amniotic membrane over a period
Correlation of Intra-Articular Ankle Pathology
Articular cartilage degeneration is mediated by inflammatory cytokines and fragments of structural matrix proteins. Few studies have examined the role of these biomarkers
Finding the Replacement for HA Injections
Jeff White is the founder and principal of Medtech Advisory Group LLC and former global director of Business Development and Licensing, Synthes Spine.
Fibronectin-Aggrecan Complex Test
FACT™ measures the presence of the Fibronectin-Aggrecan Complex (FAC) in a fluid specimen taken from patients with spine related pain
Platelet-Rich Plasma Increases
The effect of platelet-rich plasma on chondrocytes has been studied in cell and tissue culture. Less attention has been given to the effect of platelet-rich plasma
Identification of a Novel Fibronectin-Aggrecan
Molecular biomarkers associated with knee pain may be useful as diagnostic modalities, prognostic indicators, and surrogate end points for therapeutic trials.
Diagnostic Utility of Cytokine Biomarkers
The diagnosis of clinically important meniscal tears of the knee remains challenging, and it is unknown why only some injuries become painful. The role of inflammatory cytokines in
Fibronectin Aggrecan Complex Test (FACT™)
The Fibronectin Aggrecan Complex Test (FACT™) is an enzyme linked immunosorbent sandwich assay (ELISA) that measures the presence of a Fibronectin-Aggrecan Complex (FAC).
Identification of Alpha 2 Macroglobulin
Identification of Alpha 2 Macroglobulin (A2M) as a master inhibitor of cartilage degrading factors that attenuates posttraumatic osteoarthritis progression.
Identification of A2 -Macroglobulin
Identification of A2-Macroglobulin as a Master Inhibitor of Cartilage-Degrading Factors That Attenuates the Progression of Posttraumatic Osteoarthritis.
Identification of a complex between fibronectin
(Clinical Biochemistry) Identification of a complex between fibronectin and aggrecan G3 domain in synovial fluid of patients with painful meniscal pathology.
Diagnostic Utility of Cytokine Biomarkers
By Jason M. Cuellar, MD, PhD, Gaetano J. Scuderi, MD, Vanessa Gabrovsky Cuellar, MD, S. Raymond Golish, MD, PhD, and David C. Yeomans, PhD
Read the research to learn more
Identification of A2M as a master inhibitor part 2
Using Western blotting, mass spectrometry, enzyme-linked immunosorbent assay (ELISA), and immunohistochemistry, α2 M was identified as a potential therapeutic agent through a comparison of α2M concentrations in serum, synovial fluid (SF), and cartilage from normal subjects and patients with OA.
Identification of a complex between fibronectin and aggrecan G3 domain
Degenerative joint disease and joint injury are associated with increased turnover of articular cartilage proteins, inflammation and alterations to other joint tissue proteins [1,2]. Degenerative joint disease in the knee is often idiopathic, however it has also been strongly associated with prior injury such as meniscal damage.
Fibronectin Aggrecan Complex Test
The Fibronectin Aggrecan Complex Test (FACT™) is an enzyme linked immunosorbent sandwich assay (ELISA) that measures the presence of a Fibronectin-Aggrecan Complex (FAC) and other related biomarkers in a fluid specimen taken from patients with spine or joint related pain.
Finding the Replacement for HA Injections in the Knee
Jeff White is the founder and principal of Medtech Advisory Group LLC and former global director of Business Development and Licensing, Synthes Spine. He is also a member of the Board of Directors for Amedica Corporation, Liventa Bioscience and Residency Select.